Development of MW101, a Novel Adipose-Targeted siRNA, for the Treatment of Obesity
11:00 am - Thursday 10th December 2026
- Developing first-in-class, adipose-targeted RNA therapies that address the biology of obesity beyond appetite suppression
- MW101 demonstrates robust pharmacology in non-human primates and efficacy across preclinical models, supporting the potential for healthier weight loss outcomes
- Data supports exploring the opportunity for adipose-directed siRNA therapies to complement GLP-1s through distinct mechanisms of action while also serving as standalone treatment options for select patient populations
